Jazz Pharma Plc (JAZZ) Stock Price, Quote & News

Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymp...

Industry: Biotechnology

Sector: Healthcare

Phone: 353 1 634 7800

Website: www.jazzpharma.com

Address:

Waterloo Exchange, Fifth Floor Waterloo Road Dublin 4, Dublin, Ireland

Night_Owl_Biotech Feb. 6 at 1:20 AM

Commercial-stage bio share price changes last 2 days while the XBI lost 5.4%. Peak to low, the XBI was off 7%+. Read our earlier post today. 18 of the 23 in this peer group were down $URGN was the best performing bio in th peer group. There was no news nor SEC filing outside of announcing URGN will be presenting of the Guggenheim investor event. URGN hit $30 per share around Thanksgiving so Ms. Barrett has a way to go. $LEGN is off 40% since J&J presented their data at ASH, almost going down at a straight 45 degree angle the last 2 months. The fact that LEGN's share price held steady during the worst 2 days in the XBI could mean nothing but perhaps? $INCY held firm as well. INCY is the first in this peer group to report next Tuesday. We're certainly hoping they announce a SNDX acquisition Monday morning (but have no reason to suspect they will). $ADCT We have no idea why ADCT held firm after more than doubling the last 8 months. $JAZZ Research Ziihera's potential for yourself Non is next FWIW

0 · Reply

TheRealStockRocket Feb. 5 at 3:53 PM

$LEXX $MRK $TEVA $JAZZ 100% agree....on my way to 100k shares.

0 · Reply

Makingmillions192 Feb. 5 at 2:50 PM

$LEXX $MRK $TEVA $JAZZ 🔥 💰 There are several reasons partnership discussions aren’t just possible, but logical right now: 1. The asset is now “partner-ready.” Pharma wants human safety, tolerability, and comparability data — Lexaria has delivered that. 2. The 505(b)(2) pathway lowers risk with shorter timelines, lower cost, and a known molecule and market, which is attractive in a capital-constrained environment. 3. Liraglutide’s patent expiry shifts incentives — an oral, IP-protected reformulation offers a way to re-monetize an aging injectable. 4. The study design looks partner-aware: conservative dosing, tolerability focus, and clear regulatory framing generate discussion-grade data. Why no announcement yet: if discussions are active, silence is normal. Companies don’t announce exploratory talks or non-binding terms — they announce funded follow-up studies or formal collaboration and development deals.

0 · Reply

TokenTreasury Feb. 4 at 11:07 AM

$JAZZ relies on acquired products with patent exposures; pipeline sustainability is a persistent question.

0 · Reply

IN0V8 Jan. 29 at 7:43 PM

$JAZZ Buy TD Cowen raises target price to $220 from $205

0 · Reply

SuperGreenToday Jan. 29 at 1:52 PM

$JAZZ Share Price: $165.40 Contract Selected: Jun 18, 2026 $165 Calls Buy Zone: $10.67 – $13.18 Target Zone: $17.35 – $21.21 Potential Upside: 54% ROI Time to Expiration: 139 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

TradeTracs Jan. 27 at 1:53 PM

🚀Today's Top Stocks🚀 $NRIX - Tight price action $JAZZ - Strong relative strength $VRT - Daily chart inverse head and shoulders With the market coming into highs, I am waiting to see if we reject at this level before making any moves. $SPY $QQQ

0 · Reply

TradeTracs Jan. 26 at 5:12 AM

$JAZZ double inside week still flagging below its post earnings base at 173. 50sma daily support vs Friday lows very nice R:R

0 · Reply

outlawinvestor1 Jan. 26 at 4:38 AM

$ZYME $JAZZ excellent overview of the soc and potential impact of zani in gea. https://youtu.be/o53Bx2_eB5I?si=O9vWnGjSod9b6jP4

0 · Reply

Makingmillions192 Jan. 23 at 2:31 PM

$LEXX Take a min to go up-vote on Reddit!! https://www.reddit.com/r/pennystocks/s/wM8TyBuhOm $LLY $PFE $JAZZ

1 · Reply

Jazz Pharmaceuticals plc (JAZZ) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 7:05 AM EST - 24 days ago

Boehringer Ingelheim announces clinical collaboration with Jazz Pharmaceuticals to advance HER2-targeted therapy in breast cancer

Jan 9, 2026, 2:24 PM EST - 27 days ago

Jazz Pharmaceuticals plc (JAZZ) Discusses HERIZON-GEA-01 Phase III Trial Results for Zanidatamab in HER2+ GEA Transcript

Jan 9, 2026, 1:46 PM EST - 27 days ago

Jazz Pharmaceuticals: A Strong Buy Due To Execution In Oncology

Jan 8, 2026, 4:05 PM EST - 4 weeks ago

Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer

Jan 6, 2026, 1:32 PM EST - 4 weeks ago

Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall Survival Benefit

Dec 17, 2025, 4:15 PM EST - 7 weeks ago

Jazz Pharmaceuticals to Participate in Upcoming Investor Events

Dec 5, 2025, 9:00 AM EST - 2 months ago

Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting

Dec 5, 2025, 7:12 AM EST - 2 months ago

Trials, Sales Wins Sends Jazz Pharmaceuticals Higher

Dec 2, 2025, 4:05 PM EST - 2 months ago

Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium

Dec 2, 2025, 1:13 PM EST - 2 months ago

Jazz Pharmaceuticals plc (JAZZ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Nov 18, 2025, 4:15 PM EST - 2 months ago

Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference

Nov 17, 2025, 4:53 PM EST - 2 months ago

Jazz Pharmaceuticals: Stock Soars On Zanidatamab Data - I'm Still On The Fence

Nov 17, 2025, 2:43 PM EST - 2 months ago

Jazz Pharmaceuticals' And Zymeworks' Ziihera Success: A Pleasant Surprise

ZYME

Nov 17, 2025, 12:09 PM EST - 2 months ago

Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans

ZYME

Nov 17, 2025, 8:10 AM EST - 2 months ago

Jazz Pharmaceuticals and Zymeworks Report Positive Cancer Treatment Results. The Stocks Soar.

ZYME

Nov 17, 2025, 6:00 AM EST - 2 months ago

Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinom

Nov 11, 2025, 7:45 AM EST - 3 months ago

Jazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso™ (dordaviprone) in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025

Nov 5, 2025, 8:41 PM EST - 3 months ago

Jazz Pharmaceuticals plc (JAZZ) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 4:05 PM EST - 3 months ago

Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance

Nov 2, 2025, 2:24 PM EST - 3 months ago

Aristotle Global Equity Advisory Q3 2025 Contributors And Detractors

ALC CCJ FCFS LEN MCHP MLM

Oct 28, 2025, 4:05 PM EDT - 3 months ago

Jazz Pharmaceuticals Appoints Ted W. Love, M.D.

Oct 22, 2025, 4:15 PM EDT - 3 months ago

Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 5, 2025

Oct 21, 2025, 7:00 AM EDT - 3 months ago

Iambic Announces Research Collaboration with Jazz Pharmaceuticals for IAM1363 and Zanidatamab Combination Cohort in HER2-Positive Breast Cancer

Oct 17, 2025, 1:47 PM EDT - 3 months ago

3 Small Cap Stocks To Play As The Bantamweights Break Out On Wall Street

AEHR TZOO

Oct 2, 2025, 6:37 PM EDT - 4 months ago

FDA Approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Oct 2, 2025, 3:37 PM EDT - 4 months ago

US FDA approves Jazz Pharma's therapy for lung cancer

Sep 24, 2025, 10:45 AM EDT - 4 months ago

Jazz Pharmaceuticals Announces Promising Xywav Data: Why I Assign A BUY Rating

Sep 22, 2025, 7:45 AM EDT - 4 months ago

Jazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psych Congresses

Sep 9, 2025, 7:45 AM EDT - 5 months ago

Modeyso™ (dordaviprone) Included in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse Glioma

Sep 3, 2025, 1:21 PM EDT - 5 months ago

Jazz Pharmaceuticals Plc (JAZZ) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Aug 21, 2025, 4:15 PM EDT - 6 months ago

Jazz Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare Conference

Aug 20, 2025, 4:15 PM EDT - 6 months ago

Jazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025

Aug 20, 2025, 7:30 AM EDT - 6 months ago

Jazz Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355

Aug 6, 2025, 3:07 PM EDT - 6 months ago

Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma

Aug 6, 2025, 3:00 PM EDT - 6 months ago

US FDA approves Jazz Pharma's drug for rare brain tumor

Aug 6, 2025, 5:33 AM EDT - 6 months ago

Jazz Pharmaceuticals plc (JAZZ) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 4:05 PM EDT - 6 months ago

Jazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance

Jul 22, 2025, 4:15 PM EDT - 7 months ago

Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025

Jul 10, 2025, 7:30 AM EDT - 7 months ago

Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer

Jul 7, 2025, 10:05 AM EDT - 7 months ago

Is JAZZ Stock Undervalued At $110?

Jul 7, 2025, 9:30 AM EDT - 7 months ago

Jazz Pharmaceuticals: I See Big Potential In This Stock As An Investor

Jul 1, 2025, 8:31 AM EDT - 7 months ago

Jazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer

Jun 10, 2025, 7:05 AM EDT - 8 months ago

Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer

Jun 9, 2025, 6:00 PM EDT - 8 months ago

Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025

Jun 2, 2025, 4:05 PM EDT - 8 months ago

Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Significantly Improves Survival as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Jun 2, 2025, 12:35 PM EDT - 8 months ago

Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ASCO 2025

May 29, 2025, 7:30 AM EDT - 9 months ago

Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Comorbidities at SLEEP 2025

May 21, 2025, 4:30 PM EDT - 9 months ago

Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences

May 21, 2025, 4:58 AM EDT - 9 months ago

Jazz Pharmaceuticals: One Step Forward, One Back

Night_Owl_Biotech Feb. 6 at 1:20 AM

0 · Reply

TheRealStockRocket Feb. 5 at 3:53 PM

$LEXX $MRK $TEVA $JAZZ 100% agree....on my way to 100k shares.

0 · Reply

Makingmillions192 Feb. 5 at 2:50 PM

0 · Reply

TokenTreasury Feb. 4 at 11:07 AM

$JAZZ relies on acquired products with patent exposures; pipeline sustainability is a persistent question.

0 · Reply

IN0V8 Jan. 29 at 7:43 PM

$JAZZ Buy TD Cowen raises target price to $220 from $205

0 · Reply

SuperGreenToday Jan. 29 at 1:52 PM

0 · Reply

TradeTracs Jan. 27 at 1:53 PM

0 · Reply

TradeTracs Jan. 26 at 5:12 AM

$JAZZ double inside week still flagging below its post earnings base at 173. 50sma daily support vs Friday lows very nice R:R

0 · Reply

outlawinvestor1 Jan. 26 at 4:38 AM

$ZYME $JAZZ excellent overview of the soc and potential impact of zani in gea. https://youtu.be/o53Bx2_eB5I?si=O9vWnGjSod9b6jP4

0 · Reply

Makingmillions192 Jan. 23 at 2:31 PM

$LEXX Take a min to go up-vote on Reddit!! https://www.reddit.com/r/pennystocks/s/wM8TyBuhOm $LLY $PFE $JAZZ

1 · Reply

The_Wealth_Maker Jan. 23 at 2:28 PM

$LEXX $LLY $NVO $JAZZ

0 · Reply

Makingmillions192 Jan. 23 at 2:23 PM

$LEXX Can’t underestimate the update from yesterday $LLY $NVO $JAZZ Reaching 60 granted patents worldwide moves Lexaria firmly out of early-stage territory and into defensible platform status, which matters far more to pharma than pending IP. The new patents aren’t random: Europe and Australia are costly, high-value jurisdictions, signaling commercial intent. The first EU patent in hypertension is especially meaningful given Europe’s massive cardiovascular market and Lexaria’s recent blood pressure data, reinforcing alignment between clinical results and IP strategy. Expansion of the diabetes patent family in the US shortly after positive GLP-1 Phase 1b data strengthens Lexaria’s leverage exactly where partners are now focused. The emphasis on pursuing commercial relationships only after patents are granted reassures potential partners that legal risk is being actively reduced.

0 · Reply

Evo13 Jan. 22 at 3:53 PM

$JAZZ $171.28

0 · Reply

JuggernautRaider Jan. 21 at 1:46 PM

$IXHL guys a r/s to maintain NASDAQ compliance and get out of the cellar is not the end of the world. Particularly if they time it right (announce it and also expand the share buyback by another $5-10M… or, ideally, a partnership). $JAZZ is getting hosed on their oncology pipeline and Incannex would fit nicely with their epilepsy portfolio… let’s find a deal 🤝

2 · Reply

OfficialStocktwitsUser Jan. 20 at 3:18 AM

$JAZZ RSI: 48.65, MACD: 0.7615 Vol: 3.88, MA20: 168.38, MA50: 164.58 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

TradeTracs Jan. 19 at 10:42 PM

$JAZZ still supporting post earnings pop/squat, fade and recovery into 50sma, now nearly double inside day, with inside week for risk parameters

0 · Reply

Estimize Jan. 19 at 3:01 PM

Wall St is expecting 6.38 EPS for $JAZZ Q4 [Reporting 03/03 AMC] http://www.estimize.com/intro/jazz?chart=historical&metric_name=eps&utm_co

0 · Reply

JuggernautRaider Jan. 16 at 4:27 PM

Happy to. IQVIA & Symphony & Komodo are the three pharma industry leaders in sales (demand) data. biopharma data in the US is TERRIBLE given the market structure, number of different payers, et al. Often when a product is launched - particularly oral products like $TNXP Tonmya, $INCY Jakafi, $KPTI Xpovio, and even some infusion products like $JAZZ ’s Zepzelca they will block the distributors from selling the data. Usually 10-30% is not captured, but up to 60-95% can be if the pharma company only uses a few distributors & specialty pharamcies. Now this is demand or sales data - for claims data, which shows much more information (with the patient data hidden). However I doubt Tonix is doing that as it can be expensive (you have to pay them to do this - they know how valuable the data is to stock analyst & competitors). I’m hopeful we’ll see the first quarter of demand data from Tonmya soon - which will be its first month (during the holidays!) 😬 Almost to 10K shares long 💎 💪

3 · Reply

JuggernautRaider Jan. 16 at 4:15 PM

$TNXP we should see Symphony Or Komodo sales data for Tonmya soon… assuming Tonix isn’t using contracts with ira distributors to block it like $JAZZ and $KPTI and $INCY do 📊 this is a little trade secret for you all 🤫 get these shares while they’re cheap, I’m buying more ☘️ GLBB 🚀

1 · Reply

Quantumup Jan. 16 at 2:30 PM

Piper Sandler⬆️ $AXSM's PT to $223 from $148, reiterated at an Overweight and said, 'Remaining Bullish' $ACAD $JAZZ OTSKY HLUBF HLBBF JNJ TEVA Here's more of what Piper Sandler had to say: https://x.com/Quantumup1/status/2012169826177806564?s=20

0 · Reply

mpap_ Jan. 15 at 11:15 PM

$RCKT Good chances of approval for Kresladi. Solid Data. Real need for this ultra rare disease. If approved would also get a PRV, recently $JAZZ sold one for $200M . Extends runway without dilution. PT is $8-10 upon approval as may de=risk the company for the foreseeable future. If not approved then the stock will tank, runway just with cash only until 2027 Q2. As Martin Shkreli said once in his livestream, you don't want to have to beg for approval, you want to go in and have the FDA high five you and say "great job guys, making the USA proud". I think this fits this treatment and disease.

1 · Reply

Chaka1647 Jan. 14 at 9:05 PM

$FBIOP Bought more today. Risk / Reward is just outstanding. Especially since seeing that $JAZZ sold PRv for such a high number

1 · Reply

Market Cap	10.07B
Revenue (ttm)	4.07B
Net Income (ttm)	560.12M
EPS (ttm)	N/A
PE Ratio	39.54
Forward PE	8.52
Profit Margin	13.77%
Debt to Equity Ratio	1.35

Volume	627,800
Avg Vol	1,034,898
Day's Range	N/A - N/A
Shares Out	60.77M
Stochastic %K	10%
Beta	0.26
Analysts	Strong Sell
Price Target	$219.00